Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aditxt ( (ADTX) ) just unveiled an update.
On July 17, 2025, Aditxt, Inc. presented its subsidiary Pearsanta’s advancements in early disease detection at the Wall Street Reporter’s Next Super Stock livestream event. The presentation highlighted Pearsanta’s competitive edge in the diagnostics market with its Mitomic® Technology, which offers non-invasive, early detection with higher accuracy and cost-effectiveness compared to traditional methods. The company is actively pursuing regulatory approvals and strategic partnerships to expand its market reach globally, with a focus on addressing unmet clinical needs in cancer and endometriosis diagnostics.
More about Aditxt
Aditxt, Inc. operates in the biotechnology industry, focusing on innovative diagnostics through its subsidiary, Pearsanta, Inc. The company specializes in early disease detection using its proprietary Mitomic® Technology, which leverages mitochondrial DNA for non-invasive diagnostics, aiming to transform lives by detecting diseases such as cancer and endometriosis at treatable stages.
Average Trading Volume: 773,395
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.82M
See more data about ADTX stock on TipRanks’ Stock Analysis page.